Imugene (IMU) AGM 2024 summary

Opening remarks and agenda

• Meeting opened with acknowledgment of traditional landowners, confirmation of quorum, and constitution.

• AGM held in November 2024, focusing on innovation in cancer immunotherapy and company progress.

• Hybrid meeting format enabled both in-person and virtual participation, with introductions of board and management.

• Agenda adjusted to prioritize formal business due to a scheduled fire drill, followed by CEO presentation and Q&A.

Financial performance review

• Market capitalisation as of 13 November 2024: A$342M.

• Cash position as of 30 September 2024: A$54.3M (pro-forma).

Board and executive committee updates

• Dr. Jens Eckstein announced his resignation from the board after five years of service.

• Board includes experienced leaders such as Paul Hopper (Executive Chairman), Leslie Chong (CEO), and several non-executive directors with backgrounds in major pharmaceutical companies.

• Leadership team credited with bringing over 17 FDA-approved drugs to market.